AC Immune SA (ACIU)

agreement with Eli Lilly , nice

AC Immune revises collaboration with Eli Lilly on tau-targeting Alzheimer’s therapyApril 7, 2026 9:53 AM
IH Market News
AC Immune SA (NASDAQ:ACIU) said it has amended its 2018 licensing and collaboration agreement with Eli Lilly and Company (NYSE:LLY) focused on developing small-molecule tau aggregation inhibitors for Alzheimer’s disease and other neurodegenerative disorders.As part of the revised terms, AC Immune will receive an upfront payment of CHF10 million and an additional milestone payment when Phase 1 clinical dosing begins. The company remains eligible for development, regulatory and commercial milestone payments totaling more than CHF1.7 billion, along with tiered royalties in the low double-digit range.The partnership will concentrate on advancing new lead tau Morphomer candidates and potential backup molecules. AC Immune said it intends to begin Investigational New Drug (IND)-enabling studies during the first half of 2026.According to the company, the Morphomer tau compounds were chosen for their ability to cross the blood-brain barrier when taken orally and for their capacity to bind to disease-related tau protein conformations. Preclinical data suggest the molecules may help inhibit tau aggregation and seeding across different stages of disease progression.“The progress in this collaboration highlights the important breakthroughs we have made with Morphomer small molecules for intracellular targeting of Tau,” said Dr. Andrea Pfeifer, CEO of AC Immune.AC Immune is a clinical-stage biopharmaceutical company developing precision therapies for neurodegenerative diseases. Its technology platforms include SupraAntigen and Morphomer, with drug candidates currently advancing through Phase 2 and Phase 3 clinical trials.AC Immune stock price

Original: AC Immune revises collaboration with Eli Lilly on tau-targeting Alzheimer’s therapy

AC Immune begins phase 1 trial of brain-penetrant NLRP3 inhibitor
full txt = https://www.investing.com/news/company-news/ac-immune-begins-phase-1-trial-of-brainpenetrant-nlrp3-inhibitor-93CH-4521069

LAUSANNE, Switzerland - AC Immune SA (NASDAQ:ACIU) announced today that it has dosed the first participant in a Phase 1 clinical trial of ACI-19764, an oral small molecule inhibitor targeting the NLRP3 inflammasome. The clinical-stage biopharmaceutical company, with a market capitalization of $250 million, holds more cash than debt on its balance sheet according to InvestingPro data, a critical position for funding ongoing clinical trials.

The NLRP3 inflammasome is associated with chronic inflammation in multiple conditions, including Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis and frontotemporal dementia, according to the company’s press release statement.

The Phase 1 trial will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of ACI-19764 in healthy volunteers. The study consists of two parts: Part A will assess single ascending doses, while Part B will examine multiple ascending doses. The trial is being conducted in Europe.

Primary outcome measures include safety, tolerability and pharmacokinetics in plasma and cerebrospinal fluid. Secondary measures will assess target engagement through inhibition of IL-1ß, with exploratory endpoints examining the drug’s influence on immune system biomarkers.

Results from the Phase 1 trial are expected in the second half of 2026.

AC Immune

Simply Wall St Financial Health Rating: +++++_

Overview: AC Immune SA is a clinical-stage biopharmaceutical company focused on discovering, designing, and developing medicines and products for neurodegenerative diseases related to protein misfolding, with a market cap of $348.28 million.

Operations: The company's revenue segment is primarily focused on discovering and developing therapeutic and diagnostic products, generating CHF 4.37 million.

Market Cap: $348.28M

AC Immune SA, a clinical-stage biopharmaceutical company, is navigating the penny stock landscape with a market cap of $348.28 million and recent developments in its pipeline. The company remains pre-revenue, reporting CHF 0.939 million in third-quarter revenue for 2025, significantly down from the previous year. Despite this, AC Immune's financial position is relatively stable with short-term assets exceeding liabilities and no debt on its books. Recent positive interim results from a Phase 2 trial of its anti-alpha-synuclein immunotherapy for Parkinson’s disease highlight potential therapeutic advancements and have garnered attention within the biotech community.
Simply Wall St January 13, 2026

AC Immune to host webcast and conference call today at 9:00am ET / 15:00 CET

!!! AC Immune Positive Interim Phase 2 Data on ACI-7104.056 Support Potential Slowing of Progression of Parkinson’s Disease
https://finance.yahoo.com/news/ac-immune-positive-interim-phase-120000074.html

ACIU.....................................................p/m

side note
Lecanemab (Leqembi) by Biogen und Eisai >> IQWIG sees no additional benefit in the drug ...

s

ACIU Surpasses Revenue Expectations with Strong Phase 2 Data | ACIU Stock News
https://www.gurufocus.com/news/2814989/aciu-surpasses-revenue-expectations-with-strong-phase-2-data-aciu-stock-news

lows from 2023 are here, let's see

ACIU under $2

ACIU under $4

ACIU Stii in. Closed at $3.87 today, up 9.32%.

ACIU sold all yesterday at 3.46.
Rebot @ 3.35

$ACIU Added substantially in P-M @3.40.
Why go looking for a runner when ya got one!

ACIU Slow and steady wins the race!

At 2:12 pm: $3.54 +.24.... +7.28%
$3.59 HOD
Prev Close 3.30

2.8M vol.

$ACIU Being traded as it heads up. Has a catalyst this Q. Decent hold.
Bullish

AICU AC Immune Reports First Quarter 2024 Financial Results and Provides a Corporate Update
6:05 AM ET May-13-2024
AC Immune Reports First Quarter 2024 Financial Results and Provides a Corporate Update

Landmark deal announced with Takeda for ACI-24.060 with $100 million upfront and total potential payments for option exercise and milestones of up to approximately $2.1 billion
ACI-24.060 ABATE Phase 2 trial on track to report Abeta-PET imaging results in Q2 2024, evaluating amyloid plaque reduction after 6 months of anti-Abeta active immunotherapy
ACI-7104.056 VacSYn Phase 2 trial of anti-a-syn active immunotherapy in Parkinson’s disease (PD) on track for safety and immunogenicity interim data in H2 2024
Three-year cash runway with CHF 104.8 million at quarter end, plus $100 million upfront from Takeda and the anticipated ACI-35.030-related CHF 25 million milestone

$AICU Quote
AS OF 5/13/2024 11:37AM ET

$3.3399
+$1.0299 (+44.584%)
Bid x Size
$3.33 x 26
Ask x Size
$3.34 x 4
Volume
23,125,900
90 Day Avg. Vol.
166,680
Open
$3.38
Previous Close 05/10/2024
$2.31
Day Range
Low$2.88
High$3.47

AICU Will go ...can't beat the news ... and accumulation underway:

Volume
21,425,253
90 Day Avg. Vol.
166,680

128 X's the 90 DAV!!

$AICU 120 X 90 DAV!!
Have faith

Volume
20,132,107
90 Day Avg. Vol.
166,680

$ACIU Here we go..

$AICU There are a few with high shts but we'll get legs

$ACIU has the best news this morning..

$ACIU In @ 3.23. Let's go!

See my post above. But..

Lacking float + sht but still...

News this morning
Will it grow legs after 9:30

congrat$$$$ ACIU

What a day $$$$$$

I’m surprise ACIU is not trading up 200% today

WOOHOOOOOO WOOHOOOOOO awesome break out

WOOHOOOOOO WOOHOOOOOO

FDA fast track

ACIU$

ACIOU AND SOMETIMES Y

https://finviz.com/quote.ashx?t=ACIU&ty=c&ta=1&p=d

ACIU @$2.15, huge collaboration with Eli Lilly & Genentech!

ROBUST PIPELINE Addressing Alzheimer’s, Parkinson’s and other neurodegenerative diseases

"Based on our SupraAntigen® and Morphomer® technology platforms, we are advancing one of the industry’s broadest and most diverse clinical-stage pipelines focused on neurodegenerative diseases.
We design first- and best-in-class therapeutic and diagnostic candidates to tackle established and novel disease targets enabling AC Immune’s comprehensive precision medicine approach."

That`s huge! SAP founder is major shareholder with 21% stake!

AC Immune Key Shareholders

About Dietmar Hopp

About Dietmar Hopps dievini Hopp BioTech holding

CEO Andrea Pfeifer about Alzheimer & Parkinson:
(from an interview with german weekly magazine "Die Bunte", may 2022 - through google translator)
We've finally made a breakthrough in Parkinson's

Q: How is the brain destroyed in Alzheimer's and Parkinson's?

A: All neurodegenerative diseases - whether Alzheimer's, Parkinson, ALS – have one thing in common: a different protein that previously has a normal function in the body,
begins for reasons we don't even know yet, to change its structure. It becomes pathological, forms clumps and kills the nerve cells in the brain.
We want to fight these proteins. But that is great for two reasons difficult: The therapies first have to go all the way to be brought to the brain. And then they are only allowed to attack the sick protein, not the healthy one.

Q: Where do you stand in Parkinson's research?

A: We've had a groundbreaking breakthrough this year.
We have developed an imaging method that early diagnosis of Parkinson's disease could. What has been known about Alzheimer's for 20 years was for Parkinson's not yet possible. We can now to the first take a look inside the brains of Parkinson's patients and make the pathological deposits visible. That is a incredibly important first step in diagnosis and treatment development of Parkinson's disease. It's a revolution from my point of view.

Q: Why?

A: This is the only way we can make early and precise diagnoses.
When the first symptoms of Alzheimer's appear, that's it destroys up to 70 percent of nerve cells. It already exists today a blood test with a probability of more than 90 percent ability to predict whether one will fall ill. I am convinced that at some point this will also be possible with Parkinson's will be. And I also firmly believe that against both Diseases it will eventually have vaccinations.

looking good

ACIU clinical stage programs
ACI-7104 and ACI-12589
Their ACI-7104 and ACI-12589 is on alpha-synuclein for Parkinsons desease

Novel targets programs:
Anti-a-syn antibody and Morphomer® a-syn aggregation inhibitor on alpha-synuclein for Parkinsons desease
$$$

Latest ACIU news:
AC Immune Awarded New Grants from MJFF and Target ALS Supporting Programs Targeting TDP-43

ACIU had the most number of Alpha Synuclein drugs under development in 2022!!!
Parkinsons desease gamechanger on todays MJFF breakthrough news!!!!!

Parkinson Breakthrough News for ACIU
MICHAEL J. FOX FOUNDATION ANNOUNCES SIGNIFICANT BREAKTHROUGH IN SEARCH FOR PARKINSON'S BIOMARKER

alpha-synuclein is key protein here - A number of companies are involved in the development of Alpha Synuclein drugs. One of this few is AC Immune SA (ACIU) -
AC Immune SA had the most number of Alpha Synuclein drugs under development in 2022!!!
Read here about Alpha Synuclein Pipeline Drugs Market

AC Immune SA (ACIU) is currently a Nasdaq-listed 181m company! This one should rocket now!

This one running in sympathy to BIIB news from last night

Went back to single territory within 1.5 hours of trading.

Back to singles today or tomorrow imho over $110,000,000 million NEGATIVE cash flow

$0.03 revenue per share with huge negative operating margins and returns

Profitability
Profit Margin 0.00%
Operating Margin (ttm) -3,592.01%

Management Effectiveness
Return on Assets (ttm) -19.15%
Return on Equity (ttm) -33.76%

Income Statement
Revenue (ttm) 2.07M
Revenue Per Share (ttm) 0.03
Gross Profit (ttm) -44.06M
EBITDA -72.49M
Net Income Avi to Common (ttm) -74.3M
Diluted EPS (ttm) -1.12

Cash Flow Statement
Operating Cash Flow (ttm) -68.32M
Levered Free Cash Flow (ttm) -42.91M

AC Immune’s Alzheimer’s Vaccine Generates Potent Anti-pTau Antibody Response in a Phase 1b/2a Study

Interim results of ACI-35.030 vaccination show high titers of antigen-specific antibodies at potentially therapeutic levels in 100% of older patients with early Alzheimer’s disease

ACI-35.030 was safe and well tolerated with no safety concerns observed. Results support plans to further develop the Alzheimer’s vaccine into Phase 2/3

LAUSANNE, Switzerland, Feb. 11, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced positive interim results from its ongoing Phase 1b/2a clinical trial evaluating its first-in-class anti-phospho-Tau (pTau) vaccine candidate ACI-35.030 for the treatment of Alzheimer’s disease (AD). ACI-35.030 vaccination generated a potent antigen-specific antibody response against pTau in 100% of older patients with early AD, achieving antibody levels several orders of magnitude higher than pre-vaccination levels. No clinically relevant adverse events were observed. AC Immune and strategic partner Janssen Pharmaceuticals, Inc., believe these interim findings from the first two dosing groups support plans to advance the development of ACI-35.030 for the treatment of AD.

Immunization with anti-Tau vaccines represents a novel strategy for the treatment of AD and other neurodegenerative diseases characterized by Tau pathology. ACI-35.030 is a first-in-class vaccine candidate designed to generate a specific antibody response against pTau proteins in the brain. Anti-pTau antibodies generated by ACI-35.030 have the potential to reduce the spread and seeding of Tau pathology, which is a major hallmark of AD.

These new results provide encouraging clinical support for ACI-35.030, which employs a new vaccine formulation to achieve active immunization that significantly improves antibody responses in older patients with potentially attenuated immune systems. Notably, anti-pTau vaccination generates antibody responses with pharmacokinetic characteristics and target epitopes that differ substantially from the Company’s anti-Tau monoclonal antibody semorinemab, highlighting the comprehensive and complementary nature of AC Immune’s anti-Tau pipeline.

Prof. Andrea Pfeifer, CEO of AC Immune SA, commented: “These remarkable data show that ACI-35.030 is capable of generating unprecedented antibody responses against pTau in an elderly population, with very high antigen-specific titers. Importantly, it generated a much stronger antibody response compared to direct injection of exogenous antibodies. As pathological pTau is present as a precursor many years before Tau accumulation in the brain is detectable via brain imaging, such results highlight the significant promise of ACI-35.030 as an early intervention for AD, especially when combined with cutting-edge pTau diagnostics that would enable identification of people at risk of developing Tau-driven disease. We look forward to continuing to advance ACI-35.030 in our collaboration with Janssen Pharmaceuticals, Inc., as we aim to bring this potentially breakthrough vaccine to patients.”

Interim data from the Phase 1b/2a study showed:

Anti-Tau IgG response preferentially targets phosphorylated Tau in all patients;
100% of patients demonstrated an anti-pTau IgG response after the 1st injection for both lowest and second highest dosages;
Very high anti-pTau IgG titers observed following injection;
Anti-pTau IgM response was also elicited in all patients for both doses;
ACI-35.030 was safe and well tolerated with no clinically relevant safety concerns observed to date.
The companies plan to advance to the third and highest dosing group, per the study protocol.

ACI-35.030 is derived from AC Immune's proprietary SupraAntigenTM platform, which accelerates the discovery and development of conformation specific antibodies and vaccine candidates to power successful therapeutic and diagnostic approaches. Additional clinical-stage candidates derived from this platform include ACI-24, a proprietary anti-amyloid beta (Abeta) vaccine, crenezumab, an anti-Abeta monoclonal antibody, and semorinemab, an anti-Tau monoclonal antibody, which is in Phase 2 development for the treatment of moderate AD.

AC Immune’s SupraAntigenTM platform has also more recently generated conformation-specific antibodies against emerging neurodegenerative disease targets such as alpha-synuclein, TDP-43 and the NLRP3 inflammasome pathway. AC Immune’s programs directed against these emerging targets are among the most advanced and comprehensive in the field.

About the Phase 1b/2a pTau AD Vaccine Trial

AC Immune’s Phase 1b/2a pTau AD vaccine trial is a randomized, multicenter, double-blind, placebo-controlled clinical study with a primary objective to assess the safety, tolerability and immunogenicity of different doses of ACI-35.030 over a 48-week treatment phase in 32 patients with early AD. Other endpoints will assess clinical and cognitive parameters as well as additional immunogenicity and safety parameters.

About ACI-35.030

ACI-35.030 is a potent liposomal anti-pTau active investigational vaccine designed to elicit antibodies against phosphorylated pathological Tau protein. It is designed to reduce and facilitate the clearance of related Tau aggregates, slowing the progression of Tau-pathology and/or treating the underlying Tauopathy.

It builds on the success of AC Immune’s ACI-35 vaccine, which demonstrated an early target-specific antibody response against pTau after the first injection in the vast majority of participants in a Phase 1b study in mild-to-moderate AD. In preclinical studies, ACI-35.030 retained the excellent non-clinical safety profile and the highly specific antibody response against phosphorylated pathological Tau produced by ACI-35, while demonstrating an enhanced and more homogeneous antibody response.

AC Immune is developing the ACI-35.030 vaccine in collaboration with Janssen Pharmaceuticals, Inc., under a 2014 licensing agreement to develop and commercialize therapeutic anti-Tau vaccines for the treatment of AD and potentially other Tauopathies.

About AC Immune SA
AC Immune SA is a Nasdaq-listed clinical-stage biopharmaceutical company, which aims to become a global leader in precision medicine for neurodegenerative diseases. The Company utilizes two proprietary platforms, SupraAntigenTM and MorphomerTM, to design, discover and develop small molecule and biological therapeutics as well as diagnostic products intended to diagnose, prevent and modify neurodegenerative diseases caused by misfolding proteins. The Company's pipeline features nine therapeutic and three diagnostic product candidates, with six currently in clinical trials. It has collaborations with major pharmaceutical companies including Genentech, a member of the Roche Group, Eli Lilly and Company and Janssen Pharmaceuticals.

For further information, please contact:

Head of Investor Relations
Joshua Drumm, Ph.D.
AC Immune
Phone: +1 917 809 0814
Email: joshua.drumm@acimmune.com
US Media
Katie Gallagher
LaVoie Health Science
Phone: +1 617 792 3937
Email: kgallagher@lavoiehealthscience.com

European Investors & Media
Chris Maggos
LifeSci Advisors
Phone: +41 79 367 6254
Email: chris@lifesciadvisors.com
Forward looking statements
This press release contains statements that constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical fact and may include statements that address future operating, financial or business performance or AC Immune’s strategies or expectations. In some cases, you can identify these statements by forward-looking words such as “may,” “might,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “potential,” “outlook” or “continue,” and other comparable terminology. Forward-looking statements are based on management’s current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include those described under the captions “Item 3. Key Information – Risk Factors” and “Item 5. Operating and Financial Review and Prospects” in AC Immune’s Annual Report on Form 20-F and other filings with the Securities and Exchange Commission. These include: the impact of Covid-19 on our business, suppliers, patients and employees and any other impact of Covid-19. Forward-looking statements speak only as of the date they are made, and AC Immune does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law. All forward-looking statements are qualified in their entirety by this cautionary statement.


Source: AC Immune SA
© 2021 GlobeNewswire, Inc.

News: $ACIU Here's Why AC Immune Jumped Higher Today

Shares of AC Immune (NASDAQ: ACIU) a re up 26% at 2:23 p.m. EDT after the biotech revealed top-line results from an early-stage clinical trial testing its Alzheimer's disease vaccine, ACI-35.030, which A C Immune is developing with Johnson & Johnson (NYSE: JNJ) . Based on the ...

Got this from ACIU - Here's Why AC Immune Jumped Higher Today